- Home
- SNTI vs SCNX Comparison
SNTI vs SCNX Comparison
Compare SNTI & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- SCNX
- Stock Information
- Founded
- SNTI 2016
- SCNX 2010
- Country
- SNTI United States
- SCNX United States
- Employees
- SNTI N/A
- SCNX N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- SNTI Health Care
- SCNX Health Care
- Exchange
- SNTI Nasdaq
- SCNX Nasdaq
- Market Cap
- SNTI 14.1M
- SCNX 13.1M
- IPO Year
- SNTI N/A
- SCNX 2020
- Fundamental
- Price
- SNTI $2.24
- SCNX $7.16
- Analyst Decision
- SNTI
- SCNX
- Analyst Count
- SNTI 0
- SCNX 0
- Target Price
- SNTI N/A
- SCNX N/A
- AVG Volume (30 Days)
- SNTI 19.6K
- SCNX 13.1K
- Earning Date
- SNTI 11-11-2024
- SCNX 11-10-2024
- Dividend Yield
- SNTI N/A
- SCNX N/A
- EPS Growth
- SNTI N/A
- SCNX N/A
- EPS
- SNTI N/A
- SCNX N/A
- Revenue
- SNTI $338,000.00
- SCNX N/A
- Revenue This Year
- SNTI $254.47
- SCNX N/A
- Revenue Next Year
- SNTI $169.66
- SCNX N/A
- P/E Ratio
- SNTI N/A
- SCNX N/A
- Revenue Growth
- SNTI N/A
- SCNX N/A
- 52 Week Low
- SNTI $1.52
- SCNX $3.69
- 52 Week High
- SNTI $8.48
- SCNX $44.56
- Technical
- Relative Strength Index (RSI)
- SNTI 37.17
- SCNX N/A
- Support Level
- SNTI $2.05
- SCNX N/A
- Resistance Level
- SNTI $2.46
- SCNX N/A
- Average True Range (ATR)
- SNTI 0.25
- SCNX 0.00
- MACD
- SNTI -0.09
- SCNX 0.00
- Stochastic Oscillator
- SNTI 15.32
- SCNX 0.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.